Home/Gilead/William A. Lee
WA

William A. Lee

Executive Vice President, Research

Gilead

Gilead Pipeline

DrugIndicationPhase
LenacapavirHIV-1 Treatment & PreventionApproved / Phase 3
Selgantolimod (GS-9688)Chronic Hepatitis BPhase 2
Bulevirtide (Hepcludex)Chronic Hepatitis DApproved (EU) / Phase 3 (US)
Trodelvy (sacituzumab govitecan)Metastatic HR+/HER2- Breast Cancer, NSCLCApproved / Phase 3
Yescarta (axi-cel)Large B-cell LymphomaApproved / Phase 3
Domvanalimab + Zimberelimab1L Non-Small Cell Lung Cancer (NSCLC)Phase 3
GS-1811Solid TumorsPhase 1
Filgotinib (JYSELECA)Ulcerative Colitis, Crohn's DiseaseApproved (RA) / Phase 3